DK0841937T4 - Anvendelse af betaglycan til reduktion af ardannelse - Google Patents

Anvendelse af betaglycan til reduktion af ardannelse

Info

Publication number
DK0841937T4
DK0841937T4 DK96925884T DK96925884T DK0841937T4 DK 0841937 T4 DK0841937 T4 DK 0841937T4 DK 96925884 T DK96925884 T DK 96925884T DK 96925884 T DK96925884 T DK 96925884T DK 0841937 T4 DK0841937 T4 DK 0841937T4
Authority
DK
Denmark
Prior art keywords
pct
glycan
beta
date
reduce scarring
Prior art date
Application number
DK96925884T
Other languages
English (en)
Other versions
DK0841937T3 (da
Inventor
Mark William James Ferguson
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10778809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0841937(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DK0841937T3 publication Critical patent/DK0841937T3/da
Publication of DK0841937T4 publication Critical patent/DK0841937T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
DK96925884T 1995-08-04 1996-07-31 Anvendelse af betaglycan til reduktion af ardannelse DK0841937T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516073A GB2304045A (en) 1995-08-04 1995-08-04 Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
PCT/GB1996/001841 WO1997005892A1 (en) 1995-08-04 1996-07-31 Use of betaglycan to reduce scarring

Publications (2)

Publication Number Publication Date
DK0841937T3 DK0841937T3 (da) 2004-10-18
DK0841937T4 true DK0841937T4 (da) 2009-05-11

Family

ID=10778809

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96925884T DK0841937T4 (da) 1995-08-04 1996-07-31 Anvendelse af betaglycan til reduktion af ardannelse

Country Status (13)

Country Link
US (1) US6060460A (da)
EP (1) EP0841937B2 (da)
JP (1) JP4189030B2 (da)
AT (1) ATE275964T1 (da)
AU (1) AU717204B2 (da)
CA (1) CA2228650A1 (da)
DE (1) DE69633392T3 (da)
DK (1) DK0841937T4 (da)
ES (1) ES2227601T5 (da)
GB (1) GB2304045A (da)
PT (1) PT841937E (da)
WO (1) WO1997005892A1 (da)
ZA (1) ZA966577B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP1237565B1 (en) * 1999-12-15 2006-03-08 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2019236837A1 (en) * 2018-06-06 2019-12-12 Emory University Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69030956T2 (de) † 1989-09-29 1998-01-15 La Jolla Cancer Research Foundation, La Jolla, Calif. Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix
WO1991010727A1 (en) † 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
ES2191007T3 (es) † 1991-10-31 2003-09-01 Whitehead Biomedical Inst Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.
AU673506B2 (en) † 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
AU3178893A (en) * 1991-11-15 1993-06-15 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
JPH08504763A (ja) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
AU8016894A (en) * 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity

Also Published As

Publication number Publication date
EP0841937B1 (en) 2004-09-15
DE69633392T3 (de) 2009-08-13
EP0841937A1 (en) 1998-05-20
GB9516073D0 (en) 1995-10-04
US6060460A (en) 2000-05-09
JP2000500162A (ja) 2000-01-11
AU6624996A (en) 1997-03-05
ZA966577B (en) 1998-02-02
JP4189030B2 (ja) 2008-12-03
WO1997005892A1 (en) 1997-02-20
ES2227601T5 (es) 2009-06-08
ATE275964T1 (de) 2004-10-15
AU717204B2 (en) 2000-03-23
DE69633392D1 (de) 2004-10-21
DE69633392T2 (de) 2005-09-22
EP0841937B2 (en) 2009-01-14
DK0841937T3 (da) 2004-10-18
PT841937E (pt) 2004-11-30
ES2227601T3 (es) 2005-04-01
GB2304045A (en) 1997-03-12
CA2228650A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
ATE247470T1 (de) Neue substituierte imidazolverbindungen
BR0010220A (pt) Compostos de pirimidinona
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
NO963239D0 (no) Klorpyrimid-mellomprodukter
DK1143967T3 (da) Anticonvulsive derivater egnede til behandling af Hortons hovedpine
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
BG102726A (en) Combined therapy for osteoporosis
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DK0841937T3 (da) Anvendelse af betaglycan til reduktion af ardannelse
ES2195000T3 (es) Composicion farmaceutica.
ATE215084T1 (de) Imidazopyridin-azolidinone
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE59712297D1 (de) 3-alkylimidazopyridine
NO984965L (no) Komponent B som cicatrisant
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
NO974687D0 (no) Kondenserte <beta>-carboliner